Department of Life Sciences and Biotechnology, Ferrara University, 44121 Ferrara, Italy.
Laboratory for the Development of Pharmacological and Pharmacogenomic Therapy of Thalassaemia, Biotechnology Center, Ferrara University, 44121 Ferrara, Italy.
Int J Mol Sci. 2017 Nov 26;18(12):2530. doi: 10.3390/ijms18122530.
The involvement of microRNAs in the control of repressors of human gene transcription has been firmly demonstrated, as described for the miR-486-3p mediated down-regulation of BCL11A. On the other hand, we have reported that miR-210 is involved in erythroid differentiation and, possibly, in gene up-regulation. In the present study, we have identified the coding sequence of BCL11A as a possible target of miR-210. The following results sustain this hypothesis: (a) interactions between miR-210 and the miR-210 BCL11A site were demonstrated by SPR-based biomolecular interaction analysis (BIA); (b) the miR-210 site of BCL11A is conserved through molecular evolution; (c) forced expression of miR-210 leads to decrease of BCL11A-XL and increase of γ-globin mRNA content in erythroid cells, including erythroid precursors isolated from β-thalassemia patients. Our study suggests that the coding mRNA sequence of BCL11A can be targeted by miR-210. In addition to the theoretical point of view, these data are of interest from the applied point of view, supporting a novel strategy to inhibit BCL11A by mimicking miR-210 functions, accordingly with the concept supported by several papers and patent applications that inhibition of BCL11A is an efficient strategy for fetal hemoglobin induction in the treatment of β-thalassemia.
miRNAs 参与人类基因转录抑制因子的调控已得到充分证实,例如 miR-486-3p 介导的 BCL11A 下调。另一方面,我们已经报道 miR-210 参与红细胞分化,并可能参与基因上调。在本研究中,我们鉴定了 BCL11A 的编码序列作为 miR-210 的可能靶标。以下结果支持这一假设:(a)通过基于 SPR 的生物分子相互作用分析(BIA)证明了 miR-210 与 miR-210 BCL11A 结合位点之间的相互作用;(b)BCL11A 的 miR-210 结合位点在分子进化过程中是保守的;(c)在红细胞系中,包括从β地中海贫血患者中分离出的红细胞前体中,强制表达 miR-210 导致 BCL11A-XL 减少和 γ-珠蛋白 mRNA 含量增加。我们的研究表明,BCL11A 的编码 mRNA 序列可被 miR-210 靶向。除了理论观点外,这些数据从应用角度来看也很有意义,支持通过模拟 miR-210 功能来抑制 BCL11A 的新策略,这与几篇论文和专利申请的观点一致,即抑制 BCL11A 是治疗β地中海贫血症中诱导胎儿血红蛋白的有效策略。